Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Hodgkin Disease 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lopinavir × Lymphoid × Clear all
NCT01165645 2022-12-01

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Mayo Clinic

Phase NA Withdrawn
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡